Recent advances in the development of small-molecule compounds targeting HIV- 1 gp41 as membrane fusion inhibitors

Mini-Reviews in Organic Chemistry

Volumn 9, Issue 1, 2012, Pages 20-26

  Kawashita, Norihito ^a,b   Tian, Yu Shi ^a   de Silva, Chandimal U ^a,b   Okamoto, Kousuke ^a   Takagi, Tatsuya ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Coiled coil; Docking simulation; gp41; Heptad repeat; HIV; Membrane fusion; Quantitative structure activity relationship; Smallmolecule inhibitors

Indexed keywords

EID: 83455245733     PISSN: 1570193X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157019312799080080     Document Type: Article

References (45)

1. Sperling, R. Zidovudine. Infect. Dis. Obstet. Gynecol., 1998, 6, 197-203.
2. Wild, C. T.; Shugars, D. C.; Greenwell, T. K.; McDanal, C. B.; Matthews, T. J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U S A., 1994, 91, 9770-9774.
3. Sayana, S.; Khanlou, H. Maraviroc: a new CCR5 antagonist. Anti Infect.Ther. 2008, 7, 9-19.
4. Schafer, J. J.; Squires, K. E. Integrase inhibitors: a novel class of antiretroviral agents. Ann. Pharmacother. 2010, 44, 145-156.
5. Noah, E.; Biron, Z.; Naider, F.; Arshava, B.; Anglister, J. The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide. Biochemistry, 2008, 47, 6782-6792.
6. Chan, D. C.; Chutkowski, C. T.; Kim, P. S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U S A., 1998, 95, 15613-15617.
7. Eckert, D. M.; Kim, P. S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem., 2001, 70, 777-810.
8. Wyatt, R.; Sodroski, J. The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens. Science, 1998, 19, 1884-1888.
9. Jiang, S.; Lin, K.; Strick, N.; Neurath, A. R. HIV-1 inhibition by a peptide. Nature, 1993, 365, 113.
10. Isarangkura-na-ayuthaya, P.; Li, G. M.; Warachit, J.; Iwabu, Y.; Tsuji, S.; Auwanit, W.; Yamamoto, D.; Goto, T.; Hayashi, Y.; Kiso, Y.; Ikuta, K. Different susceptibility of human immunodeficiency virus type 1 to Env gp41-derived synthetic peptides corresponding to the C-terminal heptad repeat region. Microbes Infect. 2005, 7, 356-364.
11. Dwyer, J. J.; Wilson, K. L.; Davison, D. K.; Freel, S. A.; Seedorff, J. E.; Wring, S. A.; Tvermoes, N. A.; Matthews, T. J.; Greenberg, M. L.; Delmedico, M. K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. U S A., 2007, 104, 12772-12777.
12. He, Y.; Cheng, J.; Lu, H.; Li, J.; Hu, J.; Qi, Z.; Liu, Z.; Jiang, S.; Dai, Q. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc. Natl. Acad. Sci. U S A., 2008, 105, 16332-16337.
13. Naider, F.; Anglister, J. Peptides in the treatment of AIDS. Curr. Opin. Struct. Biol., 2009, 19, 473-482.
14. Pang, W.; Tam, S. C.; Zheng, Y. T. Current peptide HIV type-1 fusion inhibitors. Antivir. Chem. Chemother., 2009, 20, 1-18.
15. Otaka, A.; Nakamura, M.; Nameki, D.; Kodama, E.; Uchiyama, S.; Nakamura, S.; Nakano, H.; Tamamura, H.; Kobayashi, Y.; Matsuoka, M.; Fujii, N. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew. Chem. Int. Ed., 2002, 41, 2937-2940.
16. He, Y.; Xiao, Y.; Song, H.; Liang, Q.; Ju, D.; Chen, X.; Lu, H.; Jing, W.; Jiang, S.; Zhang, L. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem., 2008, 283, 11126-11134.
17. Soonthornsata, B.; Tian, Y. S.; Utachee, P.; Sapsutthipas, S.; Isarangkura-naayuthaya, P.; Auwanit, W.; Takagi, T.; Ikuta, K.; Sawanpanyalert, P; Kawashita, N.; Kameoka, M. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41. Virology, 2010, 405, 157-164.
18. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell, 1997, 89, 263-273.
19. Yu, H.; Tudor, D.; Alfsen, A.; Labrosse, B.; Clavel, F.; Bomsel, M. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection. Retrovirology, 2008, 5, 93-105.
20. Zwick, M. B.; Saphire, E. O.; Burton, D. R. gp41: HIV's shy protein. Nat. Med., 2004, 10, 133-134.
21. Zhou, G.; Ferrer, M.; Chopra, R.; Kapoor, T. M.; Strassmaier, T.; Weissenhorn, W.; Skehel, J. J.; Oprian, D.; Schreiber, S. L.; Harrison, S. C.; Wiley, D. C. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorg. Med. Chem., 2000, 8, 2219-2227.
22. Jiang, S.; Zhao, Q.; Debnath, A. K. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Curr. Pharm. Des. 2007, 13, 143-162.
23. Liu, S.; Jiang, S. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr. Pharm. Des. 2004, 10, 1827-1843.
24. Cai, L.; Jiang, S. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. Chem. Med. Chem. 2010, 5, 1813-1824.
25. Debnath, A. K.; Radigan, L.; Jiang, S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem., 1999, 42, 3203-3209.
26. González-Ortega, E.; Mena, M. -P.; Permanyer, M.; Ballana, E.; Clotet, B.; Esté, J. A. ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation. Antimicrob. Agents Chemother., 2010, 54, 4487-4492.
27. Ernst, J. T.; Kutzki, O.; Debnath, A. K.; Jiang, S.; Lu, H.; Hamilton, A. D. Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew. Chem. Int. Ed., 2002, 41, 278-281.
28. Tan, J. J.; Kong, R.; Chen, W. Z.; Wang, C. X. Studies on binding free energies and the binding mode by docking and MM-PBSA in gp41-ligand complex. Mol. Simul., 2005, 31, 1051-1056.
29. Zhao, Q.; Ernst, J. T.; Hamilton, A. D.; Debnath, A. K.; Jiang, S. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res. Hum. Retroviruses, 2002, 18, 989-997.
30. Ewing, T. J.; Makino, S.; Skillman, A. G.; Kuntz, I. D. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aided Mol. Des., 2001, 15, 411-428.
31. Jiang, S.; Lu, H.; Liu, S.; Zhao, Q.; He, Y.; Debnath, A. K. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents. Chemother., 2004, 48, 4349-4359.
32. Katritzky, A. R.; Tala, S. R.; Lu, H.; Vakulenko, A. V.; Chen, Q. -Y.; Sivapackiam, J.; Pandya, K.; Jiang, S.; Debnath, A. K. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3- phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors. J. Med. Chem., 2009, 52, 7631-7639.
33. Jiang, S.; Tala, S. R.; Lu, H.; Abo-Dya, N. E.; Avan, I.; Gyanda, K.; Lu, L.; Katritzky, A. R.; Debnath, A. K. Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl) phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41. J. Med. Chem., 2011, 54, 572-579.
34. Domling, A.; Ugi, I. Multicomponent Reactions with Isocyanides. Angew. Chem. Int. Ed., 2000, 39, 3168-3210.
35. Xu, Y.; Lu, H.; Kennedy, J. P.; Yan, X.; McAllister, L. A.; Yamamoto, N.; Moss, J. A.; Boldt, G. E.; Jiang, S.; Janda, K. D. Evaluation of credit card libraries for inhibition of HIV-1 gp41 fusogenic core formation. J. Comb. Chem., 2006, 8, 531-539.
36. Bao, J.; Zhang, D. W.; Zhang, J. Z. H.; Huang, P. L.; Huang, P. L.; Lee- Huang, S. Computational study of bindings of olive leaf extract (OLE) to HIV-1 fusion protein gp41. FEBS Lett., 2007, 581, 2737-2742.
37. Sun, W.; Wang, H. T.; Xia, C. L.; Wu, S. G.; Jiang, S. B.; Jiang, Z. H.; Liu, S. W. 1,2,6-tri-O-galloyl-beta-D-glucopyranose inhibits gp41-mediated HIV envelope fusion with target cell membrane. Nan Fang Yi Ke Da Xue Xue Bao, 2008, 28, 1127-1131.
38. Lü, L.; Liu, S. W.; Jiang, S. B.; Wu, S. G. Tannin inhibits HIV-1 entry by targeting gp41. Acta. Pharmacol. Sin., 2004, 25, 213-218.
39. Liu, B.; Joseph, R. W.; Dorsey, B. D.; Schiksnis, R. A.; Northrop, K.; Bukhtiyarova, M.; Springman, E. B. Structure-based design of substituted biphenyl ethylene ethers as ligands binding in the hydrophobic pocket of gp41 and blocking the helical bundle formation. Bioorg. Med. Chem. Lett., 2009, 19, 5693-5697.
40. Stewart, K. D.; Huth, J. R.; Ng, T. I.; McDaniel, K.; Hutchinson, R. N.; Stoll, V. S.; Mendoza, R. R.; Matayoshi, E. D.; Carrick, R.; Moa, H.; Severin, J.; Walter, K.; Richardson, P. L.; Barrett, L. W.; Meadows, R.; Anderson, S.; Kohlbrenner, W.; Maring, C.; Kempf, D. J.; Molla, A.; Olejniczak E. T. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket. Bioorg. Med. Chem. Lett., 2010, 20, 612-617.
41. Wang, Y.; Lu, H.; Zhu, Q.; Jiang, S.; Liao, Y. Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41. Bioorg. Med. Chem. Lett., 2010, 20, 189-192.
42. Liu, K.; Lu, H.; Qi, Z.; Teixeira, C.; Barbault, F.; Fan, B. -T.; Liu, S.; Jiang, S.; Xie, L. Design, synthesis, and biological evaluation of Ncarboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J. Med. Chem., 2008, 51, 7843-7854.
43. Zhou, G.; Wu, D.; Hermel, E.; Balogh, E.; Gochin, M. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41. Bioorg. Med. Chem. Lett., 2010, 20, 1500-1503.
44. Gochin, M.; Zhou, G.; Phillips, A. H. Paramagnetic relaxation assisted docking of a small indole compound in the HIV-1 gp41 hydrophobic pocket. ACS Chem. Biol., 2011, 6, 267-274.
45. Teixeira, C.; Barbault, F.; Rebehmed, J.; Liu, K.; Xie, L.; Lu, H.; Jiang, S.; Fan, B. T.; Maurel, F. Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors. Bioorg. Med. Chem. Lett., 2008, 16, 3039-3048.